Skip to main content
. 2017 Jan 25;8(10):16912–16924. doi: 10.18632/oncotarget.14818

Figure 3. MHY2013 exhibits potent glucose- and lipid-lowering effects without changing the body weight in genetically obese db/db mice.

Figure 3

The mice were orally treated with the vehicle (water) or 5 mg/kg/day of MHY2013 for three weeks (n = 5). A. Food intake. B. Body weight. C. Serum aspartate aminotransferase (AST), D. alanine aminotransferase (ALT), E. creatinine, F. triglyceride (TG), and G. non-esterified fatty acid (NEFA) levels. H. Glucose concentrations were determined using an intraperitoneal glucose tolerance test (ipGTT) [inset: area under the curve (AUC), mg/dL × min] by administration of 1.5 g/kg glucose after overnight fasting. I. Fasting serum glucose and J. insulin levels. The data are shown as the mean ± SEM (n = 5). *, p < 0.05 vs. db/m; **, p < 0.01 vs. db/m; ***, p < 0.001 vs. db/m; #, p < 0.05 vs. db/db; ##, p < 0.01 vs. db/db; ###, p < 0.001 vs. db/db.